Efficacy and safety of latanoprost for glaucoma treatment: A three-month multicentric study in India

Indian Journal of Ophthalmology

Volumn 53, Issue 1, 2005, Pages 23-30

  Thomas, Ravi ^a   Parikh, Rajul ^b   Sood, Devendra ^c   Vijaya, L ^d   Sekhar, G Chandra ^a   Sood, Narendra N ^c   Baskaran, M ^d   Prasad, K Kalyani ^a  

^a L V PRASAD EYE INSTITUTE   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c Shroff Eye Hospital   (India)

^d SANKARA NETHRALAYA   (India)

Author keywords

Efficacy; Glaucoma; Indian eyes; Latanoprost; Safety

Indexed keywords

LATANOPROST;

ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; DRUG EFFICACY; DRUG SAFETY; EYE IRRITATION; FEMALE; GLAUCOMA; HUMAN; INDIA; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPEN STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 17144423557     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: 10.4103/0301-4738.15281     Document Type: Article

References (24)

1. nd ed. 1996. St. Louis: Mosby-Year Book, pp 753-768.
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
3. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40.
4. Alm A, Villumsen J. Ph XA34, a new potent ocular hypotensive drug, A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991;109:1564-68.
5. 2a analogue Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992;76:214-17.
6. Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, et al. Intraocular pressure reduction with Ph XA34, a new prostagndins analogue, in patients with ocular hypertensions. Arch Ophthmol 1992;110:1733-38.
7. Kjellgren D, Douglas G, Mikelberg FS. The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand 1995;73:233-36.
8. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-32.
9. Azuara-Blanco A, Katz LJ, Spaeth GL, Wilson RP, Moster MR, Flartey KJ. Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment. Br J Ophthalmol 1997;81:1116-16.
10. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47.
11. Watson PG, The Latanoprost Study group. Latanoprost: two Years' experience of its use in United Kingdom. Ophthalmology 1998;105:82-87.
12. Alm A, Widengard, Latanoprost: Experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000;78:71-76.
13. Hedman K, Larssom LI. The Effect of Latanoprost Compared with Timolol in African-American, Asian, Caucasian, and Mexican Open-Angle Glaucoma or Ocular Hypertensive Patients. Surv Ophthalmol 2002;47:S77-S89.
14. Yasuhara H. Ethnic factors in evaluation of drug efficacy and safety. Nippon Yakurigaku Zasshi 1994;104:67-78.
15. Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol 1979;23:395-98.
16. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93.
17. Sihota R, Saxena R, Agarwal HC, Pandey RM, Gulati V. Peak pressures: crossover study of timolol and latanoprost. Eur J Ophthalmol 2003;13:546-52.
18. rd edition, Prentice Hall. 1999;70-75.
19. Bunce C, Hitchings R. Glaucoma and quality-of-life. Ophthalmology 1999;106:440-40.
20. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-95.
21. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth. Large diurnal fluctuations in intra ocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42.
22. Bron AM, Emmerich KH. Latanoprost versus combined timolol and dorzolamide. Survey Ophthalmol 2002;47:S148-S154.
23. 2a in the human eye. Graefes Archives of Ophthalmology Clin Exp Ophthalmology 1985;222:39-41.
24. 2a analogue, after topical application in normal and ocular hypertensive eyes. Arch Ophthalmol 1993;111:1351-58.